Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2023-05-12 Director's Dealing
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for insiders or major shareholders to disclose changes in their holdings, which falls under the category of 'Director's Dealing' (DIRS) as it tracks insider/major shareholder transactions and ownership status.
2023-05-12 Korean
전환가액의조정(제4회차)
Capital/Financing Update Classification · 100% confidence The document is a formal notice regarding the adjustment of the conversion price of convertible bonds (4th series) for HLB Science. It details the change in conversion price, the number of convertible shares, and the methodology used for the adjustment due to a decline in market price. This type of filing relates to changes in capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2023-05-09 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing regarding the exercise of stock options (주식매수선택권 행사) by HLB Science. It details the number of shares issued, the exercise price, the impact on total outstanding shares, and the remaining stock option balance. This type of corporate action, involving the issuance of new shares due to option exercises, falls under the category of share capital changes.
2023-04-25 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) announcing the results of an Investor Relations (IR) event held on 2023-04-20. It provides details about the event's location, participants, and where the materials were posted, rather than being the presentation itself. According to the 'Menu vs Meal' rule, this is an announcement of an event/report, which falls under the Regulatory Filings (RNS) category as it is a standard corporate disclosure of event results.
2023-04-20 Korean
[기재정정]사업보고서 (2022.12)
Regulatory Filings Classification · 95% confidence The document is a 'Correction Report' (정정신고) for an 'Annual Report' (사업보고서) filed by HLB Science Co., Ltd. It details specific corrections made to the previously submitted 2022 Annual Report, including financial statement notes, stock option details, and executive compensation information. Since this is a formal regulatory filing correcting a previously submitted annual report, it falls under the category of a regulatory filing. FY 2022
2023-04-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a 'Correction Report' (정정신고) regarding a previously filed 'Stock Option Grant' (주식매수선택권 부여에 관한 신고). It details specific corrections to the number of shares granted and the fair value calculation of the stock options. In the context of financial filings, reports concerning the issuance of stock options or changes to capital structure/equity compensation are classified under 'Share Issue/Capital Change' (SHA) as they represent changes to the company's capital structure and equity-based compensation instruments.
2023-04-13 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.